Record Net Revenues of $27.3 million and
Record ITS revenues of $17.4 million Operating Income
increased $1.3 million and Net Income increased $0.9
million
InfuSystem Holdings, Inc. (NYSE American: INFU),
(“InfuSystem” or the “Company”), a leading national health care
service provider, facilitating outpatient care for durable medical
equipment manufacturers and health care providers, today reported
financial results for the third quarter ended September 30,
2022.
Recent Events:
- November 3, 2022: Formed Wound Therapy Partnership with Sanara
MedTech – delivering a complete wound care solution to improve
patient outcomes and lower the cost of care.
- November 3, 2022: Signed distribution agreement with Cork
Medical for their negative pressure wound therapy devices and
supplies.
2022 Third Quarter
Overview:
- Net revenues totaled $27.3 million, an increase of 3% vs. prior
year.
- Integrated Therapy Services ("ITS") net revenue was $17.4
million, an increase of 5% vs. prior year.
- Durable Medical Equipment Services ("DME Services") net revenue
was $9.9 million, a decrease of 1% vs. prior year.
- Gross profit was $16.2 million, an increase of 6% vs. prior
year.
- Gross margin was 59.5%, an increase of 2.0% vs. prior year.
- ITS gross margin was 65.6%, an increase of 1.8% vs. prior
year.
- DME Services gross margin was 48.7%, an increase of 1.7% vs.
prior year.
- Operating income increased $1.3 million to $0.9 million vs.
prior year.
- Net income of $0.4 million, or $0.02 per diluted share, an
increase of $0.9 million vs. prior year.
- Adjusted earnings before interest, income taxes, depreciation,
and amortization (“Adjusted EBITDA”) (non-GAAP) was $5.6 million,
an increase of 2% vs. prior year.
- Net cash provided by operations was $13.0 million for the
nine-month period, a decrease of 11% vs. the same prior year
period.
Management Discussion
Richard DiIorio, CEO of InfuSystem, said, “The financial
performance for the third quarter was solid with record revenue of
$27.3 million and strong gross margin of 59.5%, which increased 202
basis points versus the comparable quarter last year. Our core ITS
business was the primary driver of the current quarter’s results
with record revenue of $17.4 million and a 184-basis point gross
margin increase to 65.6%. Our DME Services revenue for the quarter
was consistent with last year’s third quarter at $9.9 million and a
175-basis point gross margin increase to 48.7%. I am proud that our
talented team continues to deliver industry-leading service levels,
which we believe sets the stage for a strong business ramp going
into 2023.”
“Our recently announced strategic partnership with Sanara
MedTech significantly improves our wound care service offering,
which we expect will help accelerate our growth initiatives and
capture additional market share and revenue. Our vision is
patient-focused and geared to providing solutions that promote
healing, lower the cost of care and improve patient outcomes. The
Sanara partnership provides complementary wound care solutions and
products, expertise in the acute care setting and added experienced
sales managers. These offerings, along with a new negative pressure
wound therapy device from Cork Medical, gives us a complete line of
advanced wound care products that can be used before, during or
after therapy to promote healing throughout the continuum of care.
Combined with InfuSystem’s turnkey solution, the partnership will
soon be providing patients and providers leading-edge options for
the treatment of chronic and acute wounds.”
“We believe that the unique service solutions offered by our two
service platforms, ITS and DME Services, are well-positioned for
long-term success. We continue to execute at a high level in both
platforms, assisting our clients to effectively deliver acute care
and efficiently facilitate clinic-to-home care. We are intensely
focused on executing our strategic plan by supporting our patients
and partners with a goal of delivering sustainable growth for years
to come,” concluded Mr. DiIorio.
2022 Third Quarter Financial Review
Net revenues for the quarter ended September 30, 2022 were $27.3
million, an increase of $0.7 million, or 2.7%, compared to $26.6
million for the quarter ended September 30, 2021. The increase was
attributable to the ITS segment.
ITS net revenue of $17.4 million increased $0.8 million, or
4.8%, during the third quarter of 2022 as compared to the prior
year period. This increase was primarily attributable to additional
treatment volume in Oncology and Pain Management and improved third
party payer collections on billings. Pain Management net revenue
increased by $0.3 million for the third quarter of 2022 as compared
to the prior year third quarter due to additional sites of care
added over the last year. The higher amount represented an increase
of 37%.
DME Services net revenue of $9.9 million (exclusive of
inter-segment revenues) decreased $0.1 million, or 0.8%, during the
third quarter of 2022 as compared to the prior year period. This
decrease was due to $0.8 million in lower medical equipment sales,
partially offset by increases in revenues from equipment rentals
totaling $0.5 million, or 13%, and higher biomedical services
revenue which increased by $0.2 million, or 16%. Increased rental
revenue reflected increased market demand carried over from the
2022 second quarter as customers looked to supplement their
infusion pump fleets in the face of supply chain disruptions of
disposable medical supplies used with certain model infusion pumps.
The biomedical services revenue included initial amounts of revenue
from a new master services agreement with a leading global
healthcare technology and diagnostic company that was launched in
April 2022.
Gross profit for the third quarter of 2022 of $16.2 million
increased $1.0 million, or 6.3%, from $15.3 million for the third
quarter of 2021. The increase was driven by the increase in net
revenue and a higher gross profit percentage of net revenue ("gross
margin"). Gross margin was 59.5% during the third quarter of 2022
as compared to 57.4% during the prior year, an increase of 2.0%.
Gross margin increased in both the DME Services and ITS
segments.
ITS gross profit was $11.4 million during the third quarter of
2022, representing an increase of $0.8 million compared to the
prior year. The increase reflected the higher net revenues and a
higher gross margin, which increased from the prior year by 1.8% to
65.6%. The increase in the gross margin reflected the improved
third party payer collections on billings and improved coverage of
fixed costs from the higher net revenue.
DME Services gross profit during the third quarter of 2022 was
$4.8 million, representing an increase of $0.1 million, or 2.9%,
compared to the prior year. This increase was due to an increase in
the gross margin partially offset by lower net revenues. The DME
Services gross margin was 48.7% during the current quarter, which
was 1.7% higher than the prior year. This increase was the result
of net revenue mix favoring higher margin products and improved
biomedical technician labor productivity. The better net revenue
mix is associated with higher equipment rental revenue, which has a
higher gross margin percentage than other business lines in the DME
Services segment, and lower equipment sales revenue, which has a
lower gross margin. Improved biomedical technician labor
productivity relates to a reduced amount of training time during
the third quarter of 2022 as compared to 2021. During 2021, we
hired and trained many new biomedical technicians in anticipation
of increased biomedical services revenue volume.
Selling and marketing expenses were $2.9 million for both the
third quarter of 2022 and 2021. Selling and marketing expenses as a
percentage of net revenues decreased to 10.6% compared to the prior
year period at 10.9%. This decrease reflected improved coverage of
fixed costs from the higher net revenue.
General and administrative (“G&A”) expenses for the third
quarter of 2022 were $11.8 million, an increase of 1.7% from $11.6
million for the third quarter of 2021. The increase of $0.2 million
was due to $0.2 million in additional audit expenses associated
with additional requirements to comply with the Sarbanes-Oxley Act
of 2002, higher travel expenses and other increases including
higher personnel wages, healthcare, information technology and
general business expenses. These increases were partially offset by
a decrease in stock-based compensation expense of $0.9 million.
G&A expenses as a percentage of net revenues for the third
quarter of 2022, decreased to 43.1% compared to 43.5% for the prior
year mainly reflecting improved net revenue coverage of fixed
costs.
Net income for the third quarter of 2022 was $0.4 million, or
$0.02 per diluted share, compared to a net loss of $0.4 million, or
$(0.02) per diluted share for the third quarter of 2021.
Adjusted EBITDA, a non-GAAP measure, for the third quarter of
2022 was $5.6 million, or 20.5% of net revenue, and increased by
$0.1 million, or 2.0%, compared to Adjusted EBITDA for the same
prior year quarter of $5.5 million, or 20.7% of prior period net
revenue.
Balance sheet, cash flows and liquidity
During the nine-month period ended September 30, 2022, operating
cash flow decreased to $13.0 million, a $1.7 million or 11%
decrease over operating cash flow during the same prior year
nine-month period. The decrease reflected lower operating margins
during the year but mainly in the first quarter of 2022. Capital
expenditures, which include purchases of medical devices, totaled
$11.0 million during the nine-month period of 2022 which was $0.8
million, or 8%, higher than the amount purchased during the same
prior year period, an amount which was partially offset by higher
proceeds from the sale of medical equipment which increased by $0.4
million. Additionally, during the nine-month period of 2022, $0.8
million was used to pay contingent consideration for OB Healthcare
which was acquired in 2021 and $5.4 million was used to repurchase
the Company's common stock under a stock repurchase plan authorized
on June 30, 2021.
On February 5, 2021, the Company refinanced all of its existing
bank debt under its 2015 Credit Agreement which, at the beginning
of the 2021 first quarter, consisted of three term notes totaling
$37.9 million and a $11.8 million undrawn revolving line of credit.
The new 2021 Credit Agreement features a $75 million revolving line
of credit, does not include any term indebtedness, and matures on
the fifth anniversary of the refinancing date. The initial
borrowing under the new facility of $30 million, along with $8.2
million of our available cash, was used to repay all outstanding
obligations under the 2015 Credit Agreement. Also in February 2021,
the Company entered into two interest rate swap agreements to fix
the amount of interest expense for $20 million of the outstanding
borrowings under the loans. As a result, available liquidity
increased and debt service obligations were reduced substantially.
As of September 30, 2022, available liquidity totaled $40.1 million
and consisted of $39.7 million in available borrowing capacity
under the new revolving line of credit plus cash and cash
equivalents of $0.4 million. Net debt, a non-GAAP measure
(calculated as total debt of $34.5 million less cash and cash
equivalents of $0.4 million) as of September 30, 2022 was $34.1
million representing an increase of $1.2 million as compared to net
debt of $32.9 million as of December 31, 2021 (calculated as total
debt of $33.1 million less cash and cash equivalents of $0.2
million). Our ratio of Adjusted EBITDA to net debt (non-GAAP) for
the last four quarters was 1.56 to 1.00 (calculated as net debt of
$34.1 million divided by Adjusted EBITDA of $21.8 million).
Full Year 2022 Guidance
InfuSystem is estimating total revenue for the full year 2022 of
approximately $112 million, which is at the low end of the
previously stated guidance of 10% to 13% of revenue growth for
2022. Additionally, Adjusted EBITDA (non-GAAP) for the full year
2022 is estimated to be approximately $22 million, with Adjusted
EBITDA margin in the range of 19% to 20%.
The full year 2022 guidance reflects management’s current
expectation for operational performance, given the current market
conditions. This includes our best estimate of revenue and Adjusted
EBITDA from medical equipment sales opportunities included in our
current sales pipeline. The Company and its businesses are subject
to certain risks, including those risk factors discussed in our
most recent annual report on Form 10-K for the year ended December
31, 2021, filed on March 15, 2022. The financial guidance is
subject to risks and uncertainties applicable to all
forward-looking statements as described elsewhere in this press
release.
Conference Call
The Company will conduct a conference call for all interested
investors on Tuesday, November 8, 2022, at 9:00 a.m. Eastern Time
to discuss its third quarter 2022 financial results. The call will
include discussion of Company developments, forward-looking
statements and other material information about business and
financial matters.
To participate in this call, please dial (833) 366-1127 or (412)
902-6773, or listen via a live webcast, which is available in the
Investors section of the Company’s website at
https://ir.infusystem.com/. A replay of the call will be available
by visiting https://ir.infusystem.com/ for the next 90 days or by
calling (877) 344-7529 or (412) 317-0088, confirmation code
5564226, through November 15, 2022.
Non-GAAP Measures
This press release contains information prepared in conformity
with GAAP as well as non-GAAP financial information. Non-GAAP
financial measures presented in this press release include EBITDA,
Adjusted EBITDA, Adjusted EBITDA Margin, net debt and Adjusted
EBITDA to net debt ratio. The Company believes that the non-GAAP
financial measures presented in this press release provide useful
information to the Company’s management, investors and other
interested parties about the Company’s operating performance
because they allow them to understand and compare the Company’s
operating results during the current periods to the prior year
periods in a more consistent manner. This non-GAAP information
should be considered by the reader in addition to, but not instead
of, the financial statements prepared in accordance with GAAP, and
similarly titled non-GAAP measures may be calculated differently by
other companies. The Company calculates those non-GAAP measures by
adjusting for non-recurring or non-core items that are not part of
the normal course of business. A reconciliation of those measures
to the most directly comparable GAAP measures is provided in the
accompanying schedule, titled "GAAP to Non-GAAP Reconciliation"
below. Future period non-GAAP guidance includes adjustments for
items not indicative of our core operations, which may include,
without limitation, items included in the accompanying schedule
below. Such adjustments may be affected by changes in ongoing
assumptions and judgments, as well as non-core, nonrecurring,
unusual or unanticipated changes, expenses or gains or other items
that may not directly correlate to the underlying performance of
our business operations. The exact amounts of these adjustments are
not currently determinable but may be significant. It is therefore
not practicable to provide the comparable GAAP measures or
reconcile this non-GAAP guidance to the most comparable GAAP
measures.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading
national health care service provider, facilitating outpatient care
for durable medical equipment manufacturers and health care
providers. INFU services are provided under a two-platform model.
The first platform is Integrated Therapy Services (“ITS”),
providing the last-mile solution for clinic-to-home healthcare
where the continuing treatment involves complex durable medical
equipment and services. The ITS segment is comprised of Oncology,
Pain Management, Wound Therapy and Lymphedema businesses. The
second platform, Durable Medical Equipment Services (“DME
Services”), supports the ITS platform and leverages strong service
orientation to win incremental business from its direct payer
clients. The DME Services segment is comprised of direct payer
rentals, pump and consumable sales, and biomedical services and
repair. Headquartered in Rochester Hills, Michigan, the Company
delivers local, field-based customer support and also operates
Centers of Excellence in Michigan, Kansas, California,
Massachusetts, Texas and Ontario, Canada.
Forward-Looking Statements
The financial results in this press release reflect preliminary
results, which are not final until the Company’s quarterly report
on Form 10-Q for the quarter year ended September 30, 2022 is
filed. In addition, certain statements contained in this press
release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, such as
statements relating to future actions, our share repurchase program
and capital allocation strategy, business plans, strategic
partnerships, growth initiatives, objectives and prospects, future
operating or financial performance, guidance and expected new
business relationships and the terms thereof (including estimated
potential revenue under new or existing contracts). The words
“believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“intend,” “should,” “plan,” “goal,” “expect,” “strategy,” “future,”
“likely,” variations of such words, and other similar expressions,
as they relate to the Company, are intended to identify
forward-looking statements. Forward-looking statements are subject
to factors, risks and uncertainties that could cause actual results
to differ materially, including, but not limited to, our ability to
successfully execute on our growth initiatives and strategic
partnerships, our ability to enter into definitive agreements for
the new business relationships on expected terms or at all, our
ability to generate estimated potential revenue amounts under new
or existing contracts, the uncertain impact of the COVID-19
pandemic, our dependence on estimates of collectible revenue,
potential litigation, changes in third-party reimbursement
processes, changes in law, supply chain disruptions, contributions
from acquired businesses or new business lines, products or
services and other risk factors disclosed in the Company’s most
recent annual report on Form 10-K and, to the extent applicable,
quarterly reports on Form 10-Q. Our strategic partnerships are
subject to similar factors, risks and uncertainties. All
forward-looking statements made in this press release speak only as
of the date hereof. We do not undertake any obligation to update
any forward-looking statements to reflect future events or
circumstances, except as required by law.
Additional information about InfuSystem Holdings, Inc. is
available at www.infusystem.com.
FINANCIAL TABLES FOLLOW
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
Three Months Ended
September 30,
Nine Months Ended
September 30,
(in thousands, except share and per
share data)
2022
2021
2022
2021
Net revenues
$
27,279
$
26,566
$
81,084
$
75,863
Cost of revenues
11,060
11,308
34,597
30,979
Gross profit
16,219
15,258
46,487
44,884
Selling, general and administrative
expenses:
Provision for doubtful accounts
(90
)
10
(84
)
(99
)
Amortization of intangibles
704
1,125
2,125
3,264
Selling and marketing
2,894
2,908
9,296
7,964
General and administrative
11,768
11,566
34,525
32,537
Total selling, general and
administrative
15,276
15,609
45,862
43,666
Operating income (loss)
943
(351
)
625
1,218
Other expense:
Interest expense
(385
)
(270
)
(976
)
(909
)
Other expense
(11
)
(44
)
(69
)
(150
)
Income (Loss) before income taxes
547
(665
)
(420
)
159
(Provision for) benefit from income
taxes
(104
)
217
331
874
Net income (loss)
$
443
$
(448
)
$
(89
)
$
1,033
Net income (loss) per share:
Basic
$
0.02
$
(0.02
)
$
—
$
0.05
Diluted
$
0.02
$
(0.02
)
$
—
$
0.05
Weighted average shares outstanding:
Basic
20,683,366
20,577,886
20,625,826
20,468,842
Diluted
21,452,483
20,577,886
20,625,826
21,995,216
INFUSYSTEM HOLDINGS, INC. AND
SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS SEGMENT REPORTING (UNAUDITED)
Three Months Ended
September 30,
Better/
(Worse)
(in thousands)
2022
2021
Net revenues:
ITS
$
17,375
$
16,581
$
794
DME Services (inclusive of inter-segment
revenues)
11,514
11,425
89
Less: elimination of inter-segment
revenues
(1,610
)
(1,440
)
(170
)
Total
27,279
26,566
713
Gross profit (inclusive of certain
inter-segment allocations) (a):
ITS
11,400
10,574
826
DME Services
4,819
4,684
135
Total
$
16,219
$
15,258
$
961
(a)
Inter segment allocations are for cleaning
and repair services performed on medical equipment.
Nine Months Ended
September 30,
Better/
(Worse)
(in thousands)
2022
2021
Net revenues:
ITS
$
51,260
$
48,826
$
2,434
DME Services (inclusive of inter-segment
revenues)
34,684
31,521
3,163
Less: elimination of inter-segment
revenues
(4,860
)
(4,484
)
(376
)
Total
81,084
75,863
5,221
Gross profit (inclusive of certain
inter-segment allocations) (a):
ITS
32,251
31,028
1,223
DME Services
14,236
13,856
380
Total
$
46,487
$
44,884
$
1,603
(a)
Inter segment allocations are for cleaning
and repair services performed on medical equipment.
INFUSYSTEM HOLDINGS, INC. AND
SUBSIDIARIES GAAP TO NON-GAAP RECONCILIATION
(UNAUDITED)
NET INCOME (LOSS) TO EBITDA, ADJUSTED
EBITDA, NET INCOME (LOSS) MARGIN AND ADJUSTED EBITDA
MARGIN:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(in thousands)
2022
2021
2022
2021
GAAP net income (loss)
$
443
$
(448
)
$
(89
)
$
1,033
Adjustments:
Interest expense
385
270
976
909
Income tax provision (benefit)
104
(217
)
(331
)
(874
)
Depreciation
2,736
2,615
8,131
7,705
Amortization
704
1,125
2,125
3,264
Non-GAAP EBITDA
$
4,372
$
3,345
$
10,812
$
12,037
Stock compensation costs
1,066
1,955
3,236
4,962
Medical equipment reserve (1)
85
68
976
482
Acquisition costs
—
7
—
154
SOX readiness costs
—
68
110
86
Management reorganization/transition
costs
19
6
56
34
Certain other non-recurring costs
62
46
82
(221
)
Non-GAAP Adjusted EBITDA
$
5,604
$
5,495
$
15,272
$
17,534
GAAP Net Revenues
$
27,279
$
26,566
$
81,084
$
75,863
Net Income (Loss) Margin (2)
1.6
%
(1.7
) %
(0.1
) %
1.4
%
Non-GAAP Adjusted EBITDA Margin
(3)
20.5
%
20.7
%
18.8
%
23.1
%
(1)
Amounts represent a non-cash expense recorded to adjust the
reserve for missing medical equipment and is being added back due
to its similarity to depreciation.
(2)
Net Income (Loss) Margin is defined as GAAP Net (Loss) Income as
a percentage of GAAP Net Revenues.
(3)
Non-GAAP Adjusted EBITDA Margin is defined as Non-GAAP Adjusted
EBITDA as a percentage of GAAP Net Revenues.
INFUSYSTEM HOLDINGS, INC. AND
SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
As of
(in thousands, except par value and
share data)
September 30,
2022
December 31,
2021
ASSETS
Current assets:
Cash and cash equivalents
$
363
$
186
Accounts receivable, net
16,112
15,405
Inventories
4,861
3,939
Other current assets
2,311
2,535
Total current assets
23,647
22,065
Medical equipment for sale or rental
2,843
1,742
Medical equipment in rental service, net
of accumulated depreciation
39,202
39,871
Property & equipment, net of
accumulated depreciation
4,211
4,523
Goodwill
3,710
3,710
Intangible assets, net
8,805
10,930
Operating lease right of use assets
4,441
4,241
Deferred income taxes
9,941
10,033
Other assets
2,181
471
Total assets
$
98,981
$
97,586
LIABILITIES AND STOCKHOLDERS’
EQUITY
Current liabilities:
Accounts payable
$
6,648
$
7,862
Current portion of long-term debt
—
349
Other current liabilities
6,086
4,685
Total current liabilities
12,734
12,896
Long-term debt, net of current portion
34,461
32,748
Operating lease liabilities, net of
current portion
3,979
3,670
Total liabilities
51,174
49,314
Stockholders’ equity:
Preferred stock, $0.0001 par value:
authorized 1,000,000 shares; none issued
—
—
Common stock, $0.0001 par value:
authorized 200,000,000 shares; 20,670,049 issued and outstanding as
of September 30, 2022 and 20,699,546 issued and outstanding as of
December 31, 2021
2
2
Additional paid-in capital
105,557
101,905
Accumulated other comprehensive income
1,599
268
Retained deficit
(59,351
)
(53,903
)
Total stockholders’ equity
47,807
48,272
Total liabilities and stockholders’
equity
$
98,981
$
97,586
INFUSYSTEM HOLDINGS, INC. AND
SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended September
30,
(in
thousands)
2022
2021
OPERATING ACTIVITIES
Net (loss) income
$
(89
)
$
1,033
Adjustments to reconcile net (loss)
income to net cash provided by operating activities:
Provision for doubtful accounts
(84
)
(99
)
Depreciation
8,131
7,705
Loss on disposal of and reserve
adjustments for medical equipment
1,450
848
Gain on sale of medical equipment
(1,348
)
(1,588
)
Amortization of intangible assets
2,125
3,264
Amortization of deferred debt issuance
costs
55
132
Stock-based compensation
3,236
4,962
Deferred income taxes
(331
)
(875
)
Changes in assets -
(increase)/decrease:
Accounts receivable
(607
)
217
Inventories
(922
)
(630
)
Other current assets
224
251
Other assets
(89
)
(102
)
Changes in liabilities -
increase/(decrease):
Accounts payable and other liabilities
1,200
(513
)
NET CASH PROVIDED BY OPERATING
ACTIVITIES
12,951
14,605
INVESTING ACTIVITIES
Acquisition of business
—
(7,650
)
Purchase of medical equipment
(10,452
)
(9,645
)
Purchase of property and equipment
(571
)
(607
)
Proceeds from sale of medical equipment,
property and equipment
2,597
2,214
NET CASH USED IN INVESTING
ACTIVITIES
(8,426
)
(15,688
)
FINANCING ACTIVITIES
Principal payments on long-term debt
(31,089
)
(69,306
)
Cash proceeds from long-term debt
32,398
61,654
Debt issuance costs
—
(386
)
Cash payment of contingent
consideration
(750
)
—
Common stock repurchased to satisfy
statutory withholding on employee stock-based compensation
plans
(698
)
(1,141
)
Common stock repurchased as part of share
repurchase program
(5,359
)
—
Cash proceeds from stock plans
1,150
779
NET CASH USED IN FINANCING
ACTIVITIES
(4,348
)
(8,400
)
Net change in cash and cash
equivalents
177
(9,483
)
Cash and cash equivalents, beginning of
period
186
9,648
Cash and cash equivalents, end of
period
$
363
$
165
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221108005402/en/
Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC
602-889-9700
InfuSystems (AMEX:INFU)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
InfuSystems (AMEX:INFU)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024